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Abstract. Background: Although it is known that iNOS and
COX-2 are abundantly expressed in oral premalignant and
malignant lesions, respectively, the interaction between iNOS and
COX-2 has not been extensively studied. The purpose of this study
was to examine the alteration of the iNOS and COX-2 expression
level during hamster buccal pouch (HBP) carcinogenesis.
Materials and Methods: The expression of both iNOS and COX-
2 on normal, dysplastic mucosa and squamous cell carcinoma
(SCC) from different differentiation stages in 7, 12-
dimethylbenz[a]anthracene (DMBA)-induced HBP carcinogenesis
was examined using immunohistochemical analysis. Results: The
mean values of both iNOS and COX-2 expression increased
gradually from control to dysplastic lesions and more to invasive
SCC. The highest mean expression was SCC. The differences
between both iNOS and COX-2 expression in the normal and that
in the dysplastic and carcinoma lesions were statistically significant.
Conclusion: The results suggest that iNOS can enhance its ability
to promote tumor growth in cooperation with COX-2. The
expression of iNOS and COX-2 may be one of the factors that
contribute to oral carcinogenesis. 
Nitric oxide (NO) is a short-lived, soluble, free radical gas
produced by a variety of cells and capable of mediating a
bewildering numbers of effector functions (1). It is derived
from the amino acid L-arginine in a reaction catalyzed by
three different isoforms of nitric oxide synthase (NOS):
endothelial nitric oxide synthase (eNOS), neuronal NOS
(nNOS) and inducible NOS (iNOS) (2). iNOS produces
larger quantities of NO, which is involved in inflammation
and tumorigenesis. Besides acting as an initiator of
carcinogenesis, NO is involved in the promotional stage of
tumorigenesis or neoplastic transformation (3).
Like iNOS, COX-2 is an inducible enzyme that is not
found in normal conditions, but is induced by a variety of
pathophysiological conditions of tissues by growth factors,
inflammatory stimuli, oncogenes and tumor promoters (4,5).
Several studies show increased levels of COX-2 in
premalignant and malignant lesions, while genetic evidence
also implicates COX-2 in tumorigenesis (6-8). 
There has been an increasing body of evidence
supporting the roles of endogenous or exogenous NO in
prostaglandin (PG) biosynthesis. Under certain
pathophysiological conditions, NO and prostanoids appear
to work cooperatively and synergistically (9,10). Recent
studies indicate the NO has a profound effect on COX-2
catalytic activity and NO increases COX-2 activity (9,10).
Oral squamous cell carcinoma (OSCC) develops as a
multistep process by the accumulation of genetic and
epigenetic changes in the field exposed to the carcinogen
(11,12). This hypothesis is supported by the frequent
presence of precancerous lesions in the epithelial field of
oral cancers and the high frequency of second primary
tumors in patients definitively treated for their first oral
primary tumor (13). Histologically, carcinogenesis of the
oral mucosa is progression from normal epithelium to
hyperplastic, dysplastic lesions and invasive carcinoma (14).
The hamster buccal pouch (HBP) mucosa model is one of
the most widely accepted experimental models of human
oral cancer (15-17). Although anatomical and histological
differences between HBP and human oral mucosa are
observed, carcinogenesis protocols induce premalignant and
malignant changes that recapitulate many of the features
observed during human oral carcinogenesis (15-17). In
addition, this model is used to study the biochemical and
molecular events leading to oral cancer (17). 
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Both iNOS and COX-2 are abundantly expressed in oral
premalignant lesion and associated OSCC, respectively (18-21).
However, the interaction between iNOS and COX-2 has not
been extensively studied. In particular, the expression of
COX-2 has not been previously studied in chemically-
induced oral carcinogenesis. In this study, therefore, we
investigated the interactions between iNOS and COX-2
during 7,12-dimethylbenz[a]anthracene (DMBA)-induced
hamster buccal pouch carcinogenesis. 
Materials and Methods
Animals and treatments. Six-week-old male Syrian golden hamsters,
which weighed approximately 120 g at the beginning of the
experiment, were obtained from KIST (Taejon, Korea). The animals
were housed under controlled conditions (22ÆC, 12-h light/dark
cycle) and given standard laboratory chow and tap water ad libitum.
After allowing the animals to acclimatize for one week, both pouches
of 42 hamsters were painted with a 0.5% DMBA (D-3254; Sigma
Chemical Co., St. Louis, MO, USA) solution dissolved in mineral oil
(USP), three times weekly for 14 weeks, using a cotton pestle. The
bilateral pouches of 2 hamsters of the control group were similarly
treated with 0.2 ml of mineral oil alone. The last group of 7 hamsters
was untreated throughout the experiment. All hamsters were
sacrificed under ether anesthesia 15 weeks after commencing the
experiments. Both pouches were excised and the specimen was fixed
in 10% neutral buffered formalin and processed for the histological
and immunohistochemical examinations.
Immunohistochemistry. Immunostainings were performed by a
standard avidin-biotin peroxidase complex (ABC) method. The
previously fixed tissues were embedded in paraffin. Five-micrometer
specimens were made, which were mounted on poly-L-lysine-coated
glass slides and dried overnight at room temperature. After the
sections had been deparaffinized in xylene and rehydrated using
graded ethanol, they were immersed in 3% hydrogen peroxide in
methanol (V/V) for 15 min in order to quench the endogenous
peroxidase activity. They were then washed in TRIS buffer and
incubated with normal 1% BSA (bovine serum albumin in TRIS
buffer) for 1 h to reduce the nonspecific binding of the primary
antibody. After washing in TRIS buffer, the tissues were stained for
iNOS protein using a primary rabbit polyclonal antibody
(Calbiochem, Cat. No. 482728) and COX-2 protein using a primary
monoclonal anti-PGHS-2 (Transduction Laboratories, Lexington,
KY, USA) at 1:200 dilution overnight in a humidified chamber at
4ÆC. They were then incubated for 30 min at room temperature with
biotin-conjugated goat anti-rabbit IgG (Vector, Burlingame, USA;
1:100) and then for 30 min with ABC (DAKO, Santabara, USA). To
detect the immunoreactivity, the sections were treated with
diaminobenzidine (0.8 mM) and counterstained with hematoxylin.
Negative controls for the specificity of anti-iNOS and anti-PGHS-2
antisera were included by omitting the primary antisera.
Evaluation. The intensity of both iNOS and COX-2 in the epithelium
and tumor cells was evaluated by classifying into four groups: 0 = no;
1 = mild; 2 = moderate; and 3 = strong staining intensity. The area
of immunostainings was evaluated as follows: 0 = no positive
immunostaining, 1 = <10%; 2 = 10-25; 3 = 25-50; and 4 = >50%
showing positive immunoreactivity. A combined score for both iNOS
and COX-2 immunostainings, based on both qualitative and
quantitative immunostaining, were composed by adding the
qualitative to the quantitative score. The maximum score after adding
was 7 and the minimum, 0. The results are presented as
mean±S.E.M. Statistical significance was analyzed by using the
Student's t-test for two groups and one way analysis of variance for
multi-group comparison. P<0.05 is considered statistically significant.
Results
Histopathology. As shown in Table I, the gross and
histopathological changes in the DMBA-treated HBP
mucosa were similar to those described in our previous
study (16). Areas of dysplasia and invasive SCC with a 100%
tumor incidence developed in all of the DMBA-treated
HBP mucosa. The untreated- and mineral oil-treated
pouches showed no obvious changes, whereas the mild
hyperkeratosis and acanthosis were found in the 2-week-
DMBA-treated pouches. Mild dysplastic changes were first
observed at week 4. The severity of the dysplasia increased
in the following experimental periods. The first histological
evidence of SCC was noted in week 10 and invasive SCC
was noted in week 12 (Table I).
Immunohistochemical analysis. No iNOS activity could be
detected in the untreated or mineral oil-treated pouches.
Both cytoplasmic and nuclear stainings were observed in the
DMBA-treated HBP mucosa. There was also iNOS
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Table I. The mean values of iNOS and COX-2 expression during DMBA-induced hamster buccal pouch carcinogenesis.
Control 2W 4W 6W 8W 10W 12W 14W
Histology NM Hyp MiD MD SD CIS SCC SCC
iNOS 0.01±0.005 1.8±0.92 4.4±0.51 4.2±0.58 5±0.95 5.6±0.4 5.8±0.37 6±0.32
COX-2 0.0005±0.007 0.8±0.49 4.8±0.58 4.8±0.58 6±0.32 5.6±0.4 6±0.32 6.2±0.37
NM: Normal mucosa, Hyp: Hyperplasia, Mid: Mild dysplasia, MD: Moderate dysplasia
SD: Severe dysplasia, CIS: Carcinama in situ, SCC: Squamous cell carcinoma, Mean ± S.E.M.
expression in the stromal cells, including endothelial and
inflammatory cells. The mean values of iNOS expression
increased gradually from control to dysplastic lesions and
more to invasive SCC (Figure 1A,C,E). The highest mean
expression was SCC at week 14 (Table I). The differences
between iNOS expression in the normal and that in the
dysplastic and carcinoma lesions were statistically significant
(Figure 2). 
Normal lesions do not express substantial quantities of
COX-2. COX-2 protein is cytoplasmically detectable in
lesional epithelial cells, endothelial cells and inflammatory
cells. The immunoreactivity for COX-2 protein increased as
the tissue passed from hyperplasia to dysplasia and SCC
(Figure 1B,D,F). The highest mean expression was SCC at
week 14 (Table I). The differences between COX-2
expression in the normal and that in the dysplastic and
carcinomatous lesions was statistically significant (Figure 3). 
Discussion
In the current study, both iNOS and COX-2 immuno-
reactivities were proportional to the progression of
carcinogenesis, from epithelial hyperplasia through
dysplasia and finally to invasive carcinoma. These results
suggest that high iNOS and COX-2 activity may be closely
linked to chemically-induced multistage oral carcinogenesis.
In addition, both iNOS and COX-2 proteins have an
important role in both the early and the later stages of oral
epithelial carcinogenesis. It has been shown that both iNOS
and COX-2 proteins were expressed in premalignant and
malignant, but not normal oral and laryngeal mucosa,
suggesting that it is an immunohistochemical marker for
upper aerodigestive tract SCC (18,19,22-24). Our data is in
agreement with the results of the previous studies,
documenting a progressive increase in both iNOS and
COX-2 expression in the transition from normal mucosa
through dysplasia to invasive carcinoma, both in hamster
and human oral cancers (18,19,22,25-28). 
Excess NO could play a role in carcinogenesis by
impairing the tumor-suppressor function of p53 (29). In
addition, wild-type but not mutant p53 suppressed COX-2
transcription, raising the possibility that p53 status is also a
determinant of COX-2 expression (30). Overexpression of
COX-2 alters cell adhesion and inhibits apoptosis by
increasing the Bcl-2 protein production (31). For p53-
mutant cells, the overexpression of iNOS and COX-2 would
be unchecked and hence an up-regulation of NO and PGs
would subsequently occur, with the potential of leading to
a cancerous state (29-32). In the DMBA-induced HBP
model, p53 protein accumulation occurs frequently and
early in carcinogenesis, as it does in human SCCs, and some
of these p53 alterations are due to p53 gene mutations (15).
Therefore, it is believed that the loss of wild-type p53
function or the expression of mutant p53 in the tumor would
permit both the apoptosis and growth of the tumor in the
presence of NO and PGs. In this study, both the iNOS and
COX-2 expression level was the highest at the last stage,
SCC at week 14. This is consistent with the hypothesis that
a progressive increase of iNOS and COX-2 levels could
contribute to DMBA-induced HBP carcinogenesis by
inducing an accumulation of abnormal epithelial cells in the
invasive carcinomas. However, it was not elucidated whether
p53 mutation might result from either NO and PGs itself or
DMBA-induced genotoxicity. Recent observations support
a correlation between p53 and iNOS or COX-2 expression
for human oral epithelial dysplasia and OSCC (18-21). Cells
that carry mutant p53, especially in dysplastic lesions and
OSCCs, express high levels of iNOS and COX-2 (20,21). 
Co-induction or co-regulation of iNOS and COX-2
enzymes has been observed under diverse experimental
conditions (3). Since both genes are co-regulated by the
inflammatory mediator transcription factor NF-kappa B, the
same pathophysiological stimuli may turn on the expression
of both genes simultaneously (3,33). Alternatively, NO
produced through NF-kappa B-induced iNOS expression or
via another pathway independently of NF-kappa B, may
affect COX-2 expression/catalytic activity (3). In the current
study, we demonstrated that the expression level of iNOS
together with COX-2 was up-regulated in the dysplastic
lesion and SCC compared to normal and hyperplastic
mucosa. Thus, there is the possibility that the ability of
iNOS to promote tumor growth is enhanced in cooperation
with COX-2. However, we could not find the mechanisms
of interaction between iNOS and COX-2. 
Overall, the present study demonstrated the sequential
expression of iNOS and COX-2 in DMBA-induced HBP
carcinogenesis. Whatever the mechanisms of interaction,
this finding indicates a possible association of iNOS with
COX-2 in the development of chemically-induced oral
carcinomas. The expression of iNOS and COX-2 may be
one of the factors that contribute to oral carcinogenesis.
However, further study regarding the mechanisms of the
apparent activation of COX-2 by NO is deemed necessary
in order to evaluate the exact role of iNOS and COX-2 in
this DMBA-induced HBP carcinogenesis model. 
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